Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Electroporation Instruments Market, by Product Type (Instruments (Total Electroporation System, Transfection System, and Microbial Electroporation System) and Accessories (Electroporated Cuvettes, Electrodes, Volume Chambers, and Others)), by Application (Protein Production, Therapeutic Delivery, and Biomedical Research), by End User (Hospital Laboratories, Research & Academic Institutes, and Biotechnology or Pharmaceutical Industries), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 769.0 million in 2021, and is expected to exhibit a CAGR of 4.4% during the forecast period (2021-2028).

Rising number of product approvals and launches is expected to drive growth of the global electroporation instruments market during the forecast period. For instance, on June 25, 2020, MaxCyte, a global clinical-stage cell-based medicines and life sciences company, announced the release of the first product in its new and expanded ExPERT disposables line. The new R-1000 cuvette can process a volume of up to one mL, or up to 200 million cells, and offers greater versatility for companies developing cell therapy drugs as well as those advancing early drug discovery. These new cuvette designs can be used across the entire range of MaxCyte's electroporation instrumentation.

Due to the use of electroporation in the treatment for cancer, increase in number of public initiatives related to cancer by market players and known personalities is expected to propel the growth of the global electroporation instruments market during the forecast period. For instance, on February 03, 2021, on the eve of World Cancer Day, the European Commission unveiled Europe's Beating Cancer Plan, a key priority of the von der Leyen Commission in the area of health and a key pillar of a strong European Health Union (EHU). The Cancer Plan establishes a new EU approach to cancer prevention, treatment, and care, starting with new technologies, research, and innovation. It addresses the entire disease pathway, from prevention to cancer patient and survivor quality of life, focusing on actions where the EU can add the most value.

Global Electroporation Instruments Market- Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has a positive impact on the global electroporation instruments market, owing to the recent developments in technologies of administering DNA-based vaccines against COVID-19. For instance, according to news article published on Institute of Electrical and Electronics Engineer (IEEE) spectrum, a largest technical professional organization in the world on May 26, 2021, Inovio Pharmaceuticals, a small Pennsylvania company, is employing electroporation, a technique in which an electrical pulse applied to the skin temporarily opens channels in cells, allowing the DNA-based vaccine against COVID-19 to enter the human body. Following a standard vaccine injection, Inovio's electroporation device, which resembles an electric toothbrush, is applied to the skin. A weak electric field pulses into the arm at the press of a button, opening channels into the cells. The tool boosts the effectiveness of DNA vaccines in humans. The U.S. Department of Defense (DOD) has backed Inovio's approach with a $71 million contract to scale up production of its electroporation device, as well as an undisclosed sum to cover phase II and III studies of the company's COVID-19 vaccine. In addition, the Bill and Melinda Gates Foundation contributed US$ 5 million to the company as part of an effort to increase equitable access to COVID-19 vaccines. The clinical trials for Inovio's electroporation device are still ongoing.

Browse 33 Market Data Tables and 25 Figures spread through 167 Pages and in-depth TOC on Global Electroporation Instruments Market, by Product Type (Instruments (Total Electroporation System, Transfection System, and Microbial Electroporation System) and Accessories (Electroporated Cuvettes, Electrodes, Volume Chambers, and Others)), by Application (Protein Production, Therapeutic Delivery, and Biomedical Research), by End User (Hospital Laboratories, Research & Academic Institutes, and Biotechnology or Pharmaceutical Industries), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global electroporation instruments market, click the link below:

 https://www.coherentmarketinsights.com/market-insight/electroporation-instruments-market-4631

Key Takeaways of the Global Electroporation Instruments Market:

  • The global electroporation instruments market is expected to exhibit a CAGR of 4.4 % over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028) owing to rising agreements, collaborations and acquisitions within market players. For instance, on May 07, 2020, Caribou Biosciences Inc., a leader in CRISPR genome editing, and MaxCyte, Inc., a global cell-based therapies and life sciences company, announced a clinical and commercial license agreement. Caribou gains the right to use MaxCyte's Flow Electroporation technology and ExPERT platform to advance its CRISPR gene-edited, allogeneic T cell therapy program, according to the terms of the agreement.
  • Some of the major players operating in the global electroporation instruments market include Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Harvard Bioscience Inc. (BTX), Celetrix LLC, Mirus Bio LLC, Merck KGaA, Eppendorf AG, MaxCyte Inc., BEX Co. Ltd., and Lonza Group.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.